All News

Patients with BPDCN who did not achieve a complete or clinical complete response during treatment experienced a restoration of hematopoiesis.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Data from the QUILT-3.055 and QUILT-2.023 studies support the accelerated approval of the nogapendekin alfa inbakicept regimens in Saudi Arabia.

No grade 3 or greater treatment-related adverse effects or long-term safety signals emerged with gemogenovatucel-T in this ovarian cancer group.

Investigators will submit detailed results from the QUILT-2.023 and QUILT-3.055 trials for peer-reviewed publication and future scientific presentations.

Next steps in surgery for gastroesophageal cancer include offerings for patients with advanced disease, such as those with oligometastases.

Data from the phase 1/2 EVICTION study support the breakthrough therapy designation for ICT01 plus venetoclax/azacitidine in acute myeloid leukemia.

Osimertinib plus chemotherapy improved overall survival across various subgroups in the phase 3 FLAURA2 trial, including those with CNS metastases.

Data from the GALAXY study in Japan may inform future use of total neoadjuvant therapy among patients with rectal cancer in the US.

Any-grade AEs were comparable between cadonilimab and a PD-1 monoclonal antibody regimen in this population, and no difference in grade 3/4 AEs emerged.

The complicated nature of gastroesophageal cancer underscores the importance of collaboration between teams to safely treat patients with the disease.

Ash Tewari, MBBS, hopes that with institutional partner aid, in 10 years, 1 million men will undergo prostate cancer screening through mobile units.

Researchers highlight the importance of geriatric assessments and patient-centered outcomes to manage unique physiological and functional challenges in older breast cancer survivors.

Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.

The acceptance of the application is based on phase 3 MANEUVER study findings, in which pimicotinib improved responses vs placebo in this group.

Data from the phase 3 HARMONi trial support the application for the ivonescimab regimen in this EGFR-mutated NSCLC population.

Described as a “doctor’s office on wheels,” the mobile unit is equipped with Wi-Fi and includes point-of-care PSA/imaging tests to help bring care to patients.

Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.

The Million Strong Men Initiative is aimed at men at risk for prostate cancer who may be experiencing barriers to health care access.

The FDA no longer considers the phase 3 ALLELE trial adequate to support the approval of tabelecleucel for patients with EBV-positive PTLD.

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

Opening dialogue and establishing connections across different oncology camps may enhance the use of integrative modalities and bolster patient outcomes.

The phase 1 ARTISAN trial investigators plan to expand enrollment to patients with metastatic CRPC outside the US in the second half of 2026.

Surgeons and radiation oncologists can collaborate to discuss expected toxicity and surgical outcomes among patients with resectable gastric cancer.

Patient demands for efficacious regimens without sacrificing quality of life are driving a greater emphasis on managing and mitigating AEs in oncology.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

PFS and response rates were proved to be meaningful among patients receiving zolbetuximab plus mFOLFOX6 and nivolumab for metastatic gastric/GEJ cancer.

Any-grade AEs were observed in 91% of the pembrolizumab arm vs 82% of the placebo arm, with AEs leading to death in 1% of patients in both arms.